Related Experiment Video

Updated: May 30, 2026

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

How do we define efficacy in comparing osteoclast-targeted agents in metastatic breast cancer?

Julie R Gralow, Allan Lipton, Alison T Stopeck

    Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
    |August 17, 2011
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
    09:19

    Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

    Published on: February 6, 2015

    Models of Bone Metastasis
    08:49

    Models of Bone Metastasis

    Published on: September 4, 2012

    Related Experiment Videos

    Last Updated: May 30, 2026

    Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
    06:00

    Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

    Published on: September 13, 2017

    Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
    09:19

    Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

    Published on: February 6, 2015

    Models of Bone Metastasis
    08:49

    Models of Bone Metastasis

    Published on: September 4, 2012

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Dose-Response Relationship: Potency and Efficacy01:22

    Dose-Response Relationship: Potency and Efficacy

    The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...

    Articles linked to this work by shared authors, journal, and citation graph.

    Recurrence Score® gene group components and outcomes in the RxPONDER trial (SWOG S1007).

    Journal of the National Cancer Institute·2026

    Long-term follow-up of S0221, comparing alternative dose-schedules of anthracycline and taxane therapy in early breast cancer.

    JNCI cancer spectrum·2026

    The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial.

    JAMA oncology·2025

    The Oncology Drug Shortage: ASCO's Vision and Proposals for Resolving This Public Health Emergency.

    Cancer journal (Sudbury, Mass.)·2025

    The impacts of the Dobbs ruling on US cancer care delivery.

    Journal of the National Cancer Institute·2025

    Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    The Patient Who Could Not Die.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us